TAKEDA PHARMACEUTIC-SP ADR (TAK)
US8740602052 - ADR
Takeda Canada Inc. concludes Letter of Intent (LOI) with the pan-Canadian Pharmaceutical Alliance (pCPA) for LIVTENCITY® (maribavir) for the treatment of adults with a post-transplant cytomegalovirus (CMV) infection
/CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce that it has completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for a...
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting
Why Is AC Immune (ACIU) Stock Up 45% Today?
AC Immune stock is up on Monday after as investors in ACIU react to a new collaboration agreement with Takeda Pharmaceutical.
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
Catalyst's New CEO Has Big Ideas For The Small Biotech
Richard Daly is Catalyst Pharmaceuticals' second CEO, taking over for Patrick McEnany, who retired last year.
TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q4 2023
Takeda Pharmaceutical just reported results for the fourth quarter of 2023.
TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q4 2023
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Takeda Pharmaceutical (NYSE:TAK) just reported results for the fourth quarter o...
Takeda Announces FY2023 Full Year Results and FY2024 Outlook, Affirming Commitment to Late-Stage Pipeline Development and Core Operating Profit Margin Expansion
HUTCHMED Announces Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer Received by Takeda
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
No. 1 Biotech Stock Neurocrine Launches Higher On Depression Treatment Win
The company is establishing its line-up of drugs behind bread-and-butter med Ingrezza.
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs
/PRNewswire/ -- Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK, President and CEO; Christophe Weber, "Takeda"), Astellas Pharma Inc. (TSE: 4503,...
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
Takeda Announces New U.S. Corporate Social Responsibility Program Partners to Build Equity through STEM Education and Access to Nutritional Food
Oversold Conditions For Takeda Pharmaceutical (TAK)
Empathy in Action: Takeda's Global Initiative Brings IBD Challenges to the Forefront in the UAE
/PRNewswire/ -- Takeda, the patient-centric biopharmaceutical company, brought its global 'In Their Shoes' program to the UAE. The initiative, focused on...
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
Takeda Announces Approval of ADZYNMA® Intravenous Injection 1500 (apadamtase alfa /cinaxadamtase alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL
Takeda Announces Positive Topline Results from Phase 2 Study Evaluating Mezagitamab (TAK-079), a Potential Best-in-Class Anti-CD38 Monoclonal Antibody, for Primary Immune Thrombocytopenia
The Hot List: 3 AI Stocks Worth Buying on Weakness
Firms using AI directly can be great picks for long-term investors, such as these three AI stocks to buy on weakness.
Takeda, Biological E. to accelerate access to dengue vaccine in endemic areas (NYSE:TAK)
Takeda and Indian pharmaceutical company Biological E partner to accelerate access to dengue vaccine, aiming to reach governments in endemic countries by...
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
Championing Rare Voices on Rare Disease Day
/CNW/ - February 29th marks Rare Disease Day. On the rarest day of the year, we are reminded of the reality that 1 in 12 Canadians will be impacted by rare...
Takeda gets FDA approval for eosinophilic esophagitis drug (NYSE:TAK)
Takeda (TAK) said it has received FDA approval for its drug Eohilia for the treatment of eosinophilic esophagitis in patients 11 years and older. Read more here.
FDA Approves Takeda’s EOHILIA (budesonide oral suspension), the First and Only Oral Treatment in the U.S. for Eosinophilic Esophagitis (EoE)
Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
CRISPR CMO who resigned after Casgevy approval lands at Takeda (NASDAQ:CRSP)
Former CRISPR (CRSP) Chief Medical Officer Phuong Khanh Morrow, who resigned just days after the company won FDA approval for its gene therapy Casgevy, has landed at Takeda (TAK).
Protagonist Therapeutics stock rises on Takeda license deal (NYSE:TAK)
Protagonist Therapeutics shares surge as it enters a global collaboration with Takeda for the development of its investigational drug, rusfertide.
Takeda Pharmaceutical gets new CFO (NYSE:TAK)
Takeda announces CFO succession as Costa Saroukos steps down and Milano Furuta is appointed as his successor effective April 1, 2024.
